bioRxiv Science⌕ Search

Biology subjects

Mullins, A. J.

Publications and source records attributed to Mullins, A. J..

3 recordsLinked to original sources

Substrate scope and catalytic mechanism of α, β-epoxyketone synthase EpnF illuminated by in-situ esterase-mediated deprotection

, {beta}-Epoxyketones are an important class of bacterial natural products with wide-ranging potential applications in oncology, immunology, and infectious disease. Their clinical potential derives from the , {beta}-epoxyketone pharmacophore, which covalently modifies the N-terminal catalytic threonine residue of proteasome {beta}-subunits with high selectivity. Although a synthetic , {beta}-epoxyketone (Carfilzomib) is approved for clinical use, stereo-controlled synthesis of the pharmacophore remains challenging, involving either multiple steps and energy-intensive processes, or unsustainable reagents. Unusual flavoenzymes catalyze the assembly of the pharmacophore in , {beta}-epoxyketone biosynthesis. A detailed understanding of the substrate scope and catalytic mechanism of these enzymes has thus far been limited by the intrinsic instability of their - (di)methyl-{beta}-ketoacid substrates. Here, we report the development and application of an esterase-mediated unmasking strategy for in-situ generation of these substrates from the corresponding methyl esters. Using this approach, we demonstrate that EpnF, the epoxyketone synthase involved in eponemycin / TMC-86A biosynthesis, tolerates a broad range of synthetic substrate analogs, including several with N-terminal protecting groups widely used in peptide synthesis. These findings establish that EpnF has the potential to be developed into a useful biocatalyst for the chemoenzymatic synthesis of dipeptidyl epoxyketone precursors of clinically approved drugs and drug candidates. To elucidate the molecular basis for catalysis of , {beta}-epoxyketone formation by EpnF, substrate docking and molecular dynamics simulations were performed on a well-validated AlphaFold model, providing support for a previously proposed decarboxylation-dehydrogenation-monooxygenation mechanism. Site-directed mutagenesis and LC-MS analysis validated the proposed roles of key active-site residues in substrate positioning and catalysis of epoxide formation. Collectively, these results demonstrate that EpnF and related enzymes belong to a new class of internal flavoprotein monooxygenases and provide a foundation for developing epoxyketone synthases into useful biocatalysts for the sustainable synthesis of high-value ,{beta}-epoxyketones.

biochemistry↗

Exploration of polyyne biosynthetic gene cluster diversity in bacteria leads to the discovery of the Pseudomonas polyyne protegencin

Natural products that possess alkyne or polyyne moieties have been isolated from a variety of biological sources. In bacteria their biosynthesis has been defined, however, the distribution of polyyne biosynthetic gene clusters (BGCs), and their evolutionary relationship to alkyne biosynthesis, have not been addressed. We explored the distribution of alkyne biosynthesis gene cassettes throughout bacteria, revealing evidence of multiple horizontal gene transfer events. Investigating the evolutionary connection between alkyne and polyyne biosynthesis identified a monophyletic clade possessing a conserved seven-gene cassette for polyyne biosynthesis. Mapping the diversity of these conserved genes revealed a phylogenetic clade representing a polyyne BGC in Pseudomonas, pgn, and subsequent pathway mutagenesis and analytical chemistry characterised the associated metabolite, protegencin. In addition to unifying and expanding our knowledge of polyyne diversity, our results show that alkyne and polyyne biosynthetic gene clusters are promiscuous within bacteria. Systematic mapping of conserved biosynthetic genes across bacterial genomic diversity has proven to be a successful method for discovering natural products.

microbiology↗

Kill and cure: genomic phylogeny and bioactivity of a diverse collection of Burkholderia gladioli bacteria capable of pathogenic and beneficial lifestyles

Burkholderia gladioli is one of few bacteria with a broad ecology spanning disease in humans, animals, and plants, and encompassing beneficial interactions with multiple eukaryotic hosts. It is a plant pathogen, a bongkrekic acid toxin producing food-poisoning agent, and a lung pathogen in people with cystic fibrosis (CF). Contrasting beneficial traits include antifungal production exploited by insects to protect their eggs, plant protective abilities and antibiotic biosynthesis. We explored the ecological diversity and specialized metabolite biosynthesis of 206 B. gladioli strains, phylogenomically defining 5 evolutionary clades. Historical disease pathovars (pv) B. gladioli pv. allicola and B. gladioli pv. cocovenenans were phylogenetically distinct, while B. gladioli pv. gladioli and B. gladioli pv. agaricicola were indistinguishable. Soft-rot disease and CF infection pathogenicity traits were conserved across all pathovars. Biosynthetic gene clusters for toxoflavin, caryoynencin and enacyloxin were dispersed across B. gladioli, but bongkrekic acid and gladiolin production were clade specific. Strikingly, 13% of CF-infection strains characterised (n=194) were bongkrekic acid toxin positive, uniquely linking this food-poisoning risk factor to chronic lung disease. Toxin production was suppressed by exposing strains to the antibiotic trimethoprim, providing a potential therapeutic strategy to minimise poisoning risk in CF.

microbiology↗